Section Arrow
Quote
ALGS.NASDAQ
- Aligos Therapeutics Inc
Quotes are at least 15-min delayed:2026/04/07 10:32 EDT
Regular Hours
Last
 8.23
+0.14 (+1.73%)
Day High 
8.56 
Prev. Close
8.09 
1-M High
8.635 
Volume 
7.02K 
Bid
7.85
Ask
8.24
Day Low
7.9193 
Open
8.14 
1-M Low
6.41 
Market Cap 
49.78M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 7.21 
20-SMA 7.25 
50-SMA 7.27 
52-W High 13.6892 
52-W Low 4.13 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.45/-4.06
Enterprise Value
51.31M
Balance Sheet
Book Value Per Share
8.65
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.19M
Operating Revenue Per Share
2.66
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LNAILunai Bioworks Inc.0.3851+0.1031+36.56%-- 
SILOSilo Pharma0.4837+0.1279+35.95%-- 
TERNTerns Pharmaceuticals52.61-0.17-0.32%-- 
CUECue Biopharma0.1804+0.0034+1.92%-- 
QNCXQuince Therapeutics0.0963+0.0088+10.06%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.